The combination of GVAX pancreatic cancer vaccine, nivolumab and urelemab immunotherapy, and treatment with CD137 antibody agonists is safe, increases cancer-killing immune T cells in tumors, and is effective when given twice a week before cancer surgery.
The combination of the GVAX pancreatic cancer vaccine, nivolumab and urelemab immunotherapy, and anti-CD137 antibody treatment is safe, increases cancer-killing immune T cells in tumors, and is effective when given twice a week before … + read more
A gene present at a high level worsens the prognosis of lung and pancreatic cancer.
Researchers at Cima Universidad de Navarra suggest that blocking it will help develop more effective treatments. + read more
Trends and challenges in therapeutic cancer vaccines
Traditionally, vaccines were considered the best way to prevent infectious diseases, which is now expected to be transferred to the field of cancerous tumors. In this sense, the “boom” was caused by the study of its application, especially in the field of immunotherapy, as a therapeutic alternative to defeat cancer in the near future. + read more
M.D. Anderson Cancer Center in Madrid, world leader in oncology
M.D. Anderson Cancer Center in Houston tops the list of 300 cancer hospitals worldwide. + read more
Sant Joan de Déu Hospital Starts CAR-T ARI Clinical Trial for Childhood Lymphoblastic Leukemia
A 7-year-old girl, the first patient to receive this immunotherapy treatment, which is already being used in adults. + read more
Zoledronate and cellular immunotherapy to combat prostate cancer and its bone metastases
Enrichment of CAR-T therapy with gamma/delta T lymphocytes is essential for the benefit of this new treatment modality. + read more
Research on the link between cancer and mental retardation
The study is supported by the Uomi Cancer Center, Mi Fundación Alex and the Ricky Rubio Foundation. + read more